Tiziana Life Sciences (NASDAQ:TLSA) Given Buy Rating at BTIG Research

Tiziana Life Sciences (NASDAQ:TLSA)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a report issued on Tuesday, Benzinga reports.

TLSA has been the subject of several other reports. Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ TLSA opened at $0.90 on Tuesday. The business’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.19. Tiziana Life Sciences has a one year low of $0.76 and a one year high of $2.35.

Insiders Place Their Bets

In related news, CEO Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $1.00 per share, with a total value of $667,000.00. Following the completion of the transaction, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This represents a 17.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought 988,423 shares of company stock worth $985,909 in the last 90 days. 39.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 18.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 99,900 shares of the company’s stock after purchasing an additional 15,700 shares during the quarter. Zhang Financial LLC owned approximately 0.08% of Tiziana Life Sciences worth $149,000 at the end of the most recent reporting period.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.